Research Paper Advance Articles pp 23509—23524

FOXO3 longevity genotype mitigates the increased mortality risk in men with a cardiometabolic disease

Figure 1. Survival curves spanning the period from baseline (1991–1993) to Dec 31, 2019 for subjects with and without a CMD according to whether they were carriers of the longevity-associated G allele of SNP rs2802292. The survival probabilities were estimated from the Cox proportional hazard model (see Methods) h(t) = h(t0) * exp(β1*Age + β2*BMI + β3*Glucose + β4*CMD + β5*FOXO3_G + β6* (CMD*FOXO3_G)) by fixing age at 75 years, BMI at the mean, 23.5 kg/m2, and glucose at the mean, 113 mg/dL (where β6 is the effect of the interaction of CMD with FOXO3 genotype (G carriers vs. TT genotype) on mortality, giving P(β6) = 0.04). The P values for comparison of survival curves for the group without any CMD for FOXO3-G carriers vs. FOXO3-TT, and comparison of survival curves for the group with a CMD for FOXO3-G carriers vs. FOXO3-TT, were P=0.97 and P=0.0002, respectively. The P-values for comparison of survival curves for FOXO3-TT carriers or for FOXO3-G carriers for those with a CMD versus those without any CMD, were P=0.000039 and P=0.28 respectively.